Humana (OM:HUM) Stock Shrugs Off Q3 Earnings Rebound As Margin Questions Linger

Humana’s Q3 2026 report dropped into a stock that had been quietly grinding higher in recent months, with the shares closing at SEK70.4 just before the release. The fresh numbers put one thing front and center for sentiment: profitability snapped back. Basic earnings per share landed at SEK2.59 for the quarter, paired with SEK2,595m in revenue, after a choppy run that even included a small loss in Q2. The question for investors now is whether today’s calm price reaction reflects discipline or a market underestimating how sharply the earnings picture has flipped.

Love the earnings rebound at Humana but concerned about how repeatable that kind of turnaround is quarter to quarter? Use our curated screener of stocks that pair resilient earnings power with solid balance sheets as a benchmark through the list of solid balance sheet and fundamentals stocks (204 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): SEK2,595m vs. SEK2,489m (up about 4.3%)
• Net Income, Excl. Extra Items (Q3 2026 vs Q3 2025): SEK123m vs. SEK120m (up about 2.5%)
• Basic EPS (Q3 2026 vs Q3 2025): SEK2.59 vs. SEK2.42 (up about 6.8%)
• Trailing Net Margin (Last 12 Months vs Prior Year): 1.8% vs. 2.3% (margin has weakened over the period)

Ask Charlie what Humana’s one-off gain means for real earnings.

Humana’s High‑Margin Expansion Story Meets Early Proof

Supporters of Humana argue that higher margin units and better use of capacity will steadily reshape the earnings profile. The clearest expression of that ambition sits here:

"Expansion in higher margin Elderly Care and LSS group homes, including newly signed units in Sweden and Norway, is set to add about SEK 140 million in yearly revenues and can lift group revenue mix and EBIT margin over time."

Q3 results show this thesis starting to connect with reality. Revenue is up year on year, earnings recovered sharply from the Q2 loss, and basic EPS improved versus Q3 2025. That rebound comes even as the trailing net margin is still softer than last year, which means the high margin mix shift is underway but not yet fully visible in the 12 month profitability line.

One Narrative disagrees with today's price. → See where this Narrative says Humana should trade.

Humana Bear Case: Efficiency Gains Still Getting Tripped Up

The cautious view argues that Humana’s margin work will be blunted by execution friction rather than demand. That worry is clearest here.

"Although the efficiency program and AI driven digitalization are starting to support margins in Sweden, the need for continued investment in systems and temporary implementation costs could limit how much of the operational improvement actually flows through to EBIT and earnings."

Q3 shows this concern has not been fully cleared. Basic EPS rebounded to SEK2.59 and net income excluding extra items reached SEK123m, yet the trailing net margin sits at 1.8% compared with 2.3% a year earlier. Profitability over 12 months still reflects the implementation drag bears worry about.

Hunt For Mispriced Earnings Power

Humana recently showed how earnings expectations can change even when the share price holds relatively steady. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 45% below our estimate - monetizes leaner working capital and higher operating cash flow from new GLP-1, menopausal, and oncology launches.
• Company 2 - 42% below our estimate - scales mortgage, housing, and insurance platforms as loss-making units move toward profitability on largely fixed infrastructure.
• Company 3 - 44% below our estimate - executes an efficiency program and capital plan so higher aircraft build rates support stronger free cash flow and margins.

That is three of the list. See all 191 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com